Shaping magnetic fields to direct therapy to ears and eyes

Annual Review of Biomedical Engineering

Volumn 16, Issue , 2014, Pages 455-481

  Shapiro, B ^a   Kulkarni, S ^a   Nacev, A ^a   Sarwar, A ^a   Preciado, D ^b   Depireux, D A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

drug delivery; ear; eye; magnetic targeting; nanotherapy; stem cells

Indexed keywords

DISEASE CONTROL; DRUG DELIVERY; MAGNETIC FIELDS; MAGNETS; STEM CELLS;

EAR; EYE; HUMAN PATIENTS; MAGNET SYSTEMS; MAGNETIC NANO-PARTICLES; MAGNETIC TARGETING; NANOTHERAPY; SPACE AND TIME;

ELECTROMAGNETIC FIELD EFFECTS;

NANOPARTICLE;

DRUG DELIVERY SYSTEM; EAR; EYE; INNER EAR; MAGNETIC FIELD; MIDDLE EAR; PERILYMPH; REVIEW; STEM CELL; ANIMAL; BLINDNESS; DIABETES MELLITUS; ELECTROMAGNETIC FIELD; ENDOPHTHALMITIS; EQUIPMENT DESIGN; HUMAN; MACULAR DEGENERATION; MAGNETISM; PATHOLOGY; RETINAL DISEASES; RETINITIS PIGMENTOSA; VISUAL SYSTEM FUNCTION;

ANIMALS; BLINDNESS; DIABETES COMPLICATIONS; DRUG DELIVERY SYSTEMS; EAR; EAR, INNER; EAR, MIDDLE; ELECTROMAGNETIC PHENOMENA; ENDOPHTHALMITIS; EQUIPMENT DESIGN; EYE; HUMANS; MACULAR DEGENERATION; MAGNETIC FIELDS; MAGNETICS; OCULAR PHYSIOLOGICAL PHENOMENA; RETINAL DISEASES; RETINITIS PIGMENTOSA;

EID: 84904287114     PISSN: 15239829     EISSN: 15454274     Source Type: Book Series    
DOI: 10.1146/annurev-bioeng-071813-105206     Document Type: Review

References (238)

1. Reszka R, Beck P, Fichtner I, Hentschel M, Richter J, Kreuter J. 1997. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice. J. Pharmacol. Exp. Ther. 280(1):232-37
2. Davies NM. 2000. Biopharmaceutical considerations in topical ocular drug delivery. Clin. Exp. Pharmacol. Physiol. 27(7):558-62
3. Parnes LS, Sun A-H, Freeman DJ. 1999. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 109(S91):1-17
4. Juhn SK, Hunter BA, Odland RM. 2001. Blood-labyrinth barrier and fluid dynamics of the inner ear. Int. Tinnitus J. 7(2):72-83
5. Inamura N, Salt AN. 1992. Permeability changes of the blood-labyrinth barrier measured in vivo during experimental treatments. Hear. Res. 61(1-2):12-18
6. Orekhova NM, Akchurin RS, Belyaev AA, Smirnov MD, Ragimov SE, Orekhov AN. 1990. Local prevention of thrombosis in animal arteries by means of magnetic targeting of aspirin-loaded red cells. Thromb. Res. 57(4):611-16
7. /-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 56(20):4686-93
8. Shinkai M. 2002. Functional magnetic particles for medical application. J. Biosci. Bioeng. 94(6):606-13
9. Alexiou C, Jurgons R, Schmid RJ, Bergemann C, Henke J, et al. 2003. Magnetic drug targeting- biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J. Drug Target. 11(3):139-49
10. Wilson MW, Kerlan RK, Fidelman NA, Venook AP, LaBerge JM, et al. 2004. Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/conventional angiography suite-initial experience with four patients. Radiology 230(1):287-93
11. Koda J, Venook A, Walser E, Goodwin S. 2002. A multicenter, phase I/II trial of hepatic intra-arterial delivery of doxorubicin hydrochloride adsorbed to magnetic targeted carriers in patients with hepatocellular carcinoma. Eur. J. Cancer 38(Suppl. 7):S18
12. Johannsen M, Gneveckow U, Eckelt L, Feussner A, Waldöfner N, et al. 2005. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int. J. Hyperthermia 21(7):637-47
13. Dobson J. 2006. Magnetic micro-and nano-particle-based targeting for drug and gene delivery. Nanomedicine 1(1):31-37
14. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, et al. 2010. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neuro-Oncol. 103(2):317-24
15. Morishita N, Nakagami H, Morishita R, Takeda S, Mishima F. 2005. Magnetic nanoparticles with surface modification enhanced gene delivery of HVJ-E vector. Biochem. Biophys. Res. Commun. 334(4):1121-26
16. Mah C, Fraites TJ, Zolotukhin I, Song S, Flotte TR, et al. 2002. Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol. Ther. 6(1):106-12
17. Lu J, Ma S, Sun J, Xia C, Liu C, et al. 2009. Manganese ferrite nanoparticle micellar nanocomposites as MRI contrast agent for liver imaging. Biomaterials 30(15):2919-28
18. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. 2001. Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. Int. J. Oncol. 18(1):121-26
19. Wu J, Leong-Poi H, Bin J, Yang L, Liao Y, et al. 2011. Efficacy of contrast-enhanced US and magnetic microbubbles targeted to vascular cell adhesion molecule-1 for molecular imaging of atherosclerosis. Radiology 260(2):463-71
20. Kong SD, Lee J, Ramachandran S, Eliceiri BP, Shubayev VI, et al. 2012. Magnetic targeting of nanopar-ticles across the intact blood-brain barrier. J. Control. Release 164(1):49-57
21. 4/Salicylic acid nanoparticles behavior on chick CAM vasculature. J. Nanopart. Res. 15:1857
22. Stanley SA, Gagner JE, Damanpour S, Yoshida M, Dordick JS, Friedman JM. 2012. Radio-wave heating of iron oxide nanoparticles can regulate plasma glucose in mice. Science 336(6081):604-8
23. Cho MH, Lee EJ, Son M, Lee J-H, Yoo D, et al. 2012. A magnetic switch for the control of cell death signalling in in vitro and in vivo systems. Nat. Mater. 11:1038-43
24. Gao F, Kar S, Zhang J, Qiu B, Walczak P, et al. 2007. MRI of intravenously injected bone marrow cells homing to the site of injured arteries. NMR Biomed. 20(7):673-81
25. Pislaru SV, Harbuzariu A, Gulati R, Witt T, Sandhu NP, et al. 2006. Magnetically targeted endothelial cell localization in stented vessels. J. Am. Coll. Cardiol. 48(9):1839-45
26. Gazeau F, Wilhelm C. 2010. Magnetic labeling, imaging and manipulation of endothelial progenitor cells using iron oxide nanoparticles. Future Med. Chem. 2(3):397-408
27. Pawelczyk E, Jordan EK, Balakumaran A, Chaudhry A, Gormley N, et al. 2009. In vivo transfer of intracellular labels from locally implanted bone marrow stromal cells to resident tissue macrophages. PLoS ONE 4(8):e6712
28. Arbab AS, Jordan EK, Wilson LB, Yocum GT, Lewis BK, Frank JA. 2004. In vivo trafficking and targeted delivery of magnetically labeled stem cells. Hum. Gene Ther. 15(4):351-60
29. Chen J, Jia Z-Y, Ma Z-L, Wang Y-Y, Teng G-J. 2011. In vivo serial MR imaging of magnetically labeled endothelial progenitor cells homing to the endothelium injured artery in mice. PLoS ONE 6(6):e20790
30. Qiu B, Gao F, Walczak P, Zhang J, Kar S, et al. 2007. Invivo MR imagingofbone marrow cells trafficking to atherosclerotic plaques. J. Magn. Reson. Imaging 26(2):339-43
31. Polyak B, Fishbein I, Chorny M, Alferiev I, Williams D, et al. 2008. High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc. Natl. Acad. Sci. USA 105(2):698-703
32. Yanai A, Häfeli UO, Metcalfe AL, Soema P, Addo L, et al. 2012. Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles. Cell Transplant. 21(6):1137-48
33. Hofmann A, Wenzel D, Becher UM, Freitag DF, Klein AM, et al. 2009. Combined targeting of lentivi-ral vectors and positioning of transduced cells by magnetic nanoparticles. Proc. Natl. Acad. Sci. USA 106(1):44-49
34. Chaudeurge A, Wilhelm C, Chen-Tournoux A, Farahmand P, Bellamy V, et al. 2012. Can magnetic targeting of magnetically labeled circulating cells optimize intramyocardial cell retention? Cell Transplant. 21(4):679-91
35. Dougherty TJ, Gomer CJ, Jori G, Kessel D, Korbelik M, et al. 1998. Photodynamic therapy. J. Natl. Cancer Inst. 90(12):889-905
36. Barry BW. 2001. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur. J. Pharm. Sci. 14(2):101-14
37. Denet AR, Vanbever R, Preat V. 2004. Skin electroporation for transdermal and topical delivery. Adv. Drug Deliv. Rev. 56(5):659-74
38. Pitt WG, Husseini GA, Staples BJ. 2004. Ultrasonic drug delivery- A general review. Expert Opin. Drug Deliv. 1(1):37-56
39. Gao Z-G, Fain HD, Rapoport N. 2005. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J. Control. Release 102(1):203-22
40. Allen ED, Burdette JH. 2001. Questions and Answers in MRI. St. Louis, MO: Mosby. 2nd ed.
41. Schenck JF. 2000. Safety of strong, static magnetic fields. J. Magn. Reson. Imaging 12(1):2-19
42. Schaefer DJ, Bourland JD, Nyenhuis JA. 2000. Review of patient safety in time-varying gradient fields. J. Magn. Reson. Imaging 12(1):20-29
43. Andersen E. 2007. Magnetic resonance imaging-safety and health issues. AAOHN J. 55(4):137-39
44. Kirui DK, Khalidov I, Wang Y, Batt CA. 2013. Targeted near-IR hybrid magnetic nanoparticles for in vivo cancer therapy and imaging. Nanomed.: Nanotechnol. Biol. Med. 9(5):702-11
45. Lemke A, Sander B, Luebbe A, Riess H, Hosten N, Felix R. 1996. MR imaging after magnetic drug targeting in patients with soft-tissue tumors. Radiology 201:1421
46. Johannsen M, Gneveckow U, Thiesen B, Taymoorian K, Cho CH, et al. 2007. Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. Eur. Urol. 52(6):1653-61
47. Lemke AJ, Von Pilsach MIS, Lübbe A, Bergemann C, Riess H, Felix R. 2004. MRI after magnetic drug targeting in patients with advanced solid malignant tumors. Eur. Radiol. 14(11):1949-55
48. Widder KJ, Morris RM, Poore G, Howard DP, Senyei AE. 1981. Tumor remission in Yoshida sarcoma-bearing rats by selective targeting of magnetic albumin microspheres containing doxorubicin. Proc. Natl. Acad. Sci. USA 78(1):579-81
49. Pulfer SK, Gallo JM. 1998. Enhanced brain tumor selectivity of cationic magnetic polysaccharide mi-crospheres. J. Drug Target. 6(3):215-27
50. Krukemeyer MG, Krenn V, Jakobs M, Wagner W. 2012. Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver-magnetic nanoparticles in cancer treatment. J. Surg. Res. 175(1):35-43
51. Pouponneau P, Leroux J-C, Soulez G, Gaboury L, Martel S. 2011. Co-encapsulation of magnetic nanoparticles and doxorubicin into biodegradable microcarriers for deep tissue targeting by vascular MRI navigation. Biomaterials 32(13):3481-86
52. Raut SL, Kirthivasan B, Bommana MM, Squillante E, Sadoqi M. 2010. The formulation, characterization and in vivo evaluation of a magnetic carrier for brain delivery of NIR dye. Nanotechnology 21(39):395102
53. Pouponneau P, Leroux J-C, Martel S. 2009. Magnetic nanoparticles encapsulated into biodegradable microparticles steered with an upgraded magnetic resonance imaging system for tumor chemoemboliza-tion. Biomaterials 30(31):6327-32
54. Liu H-L, Hua M-Y, Yang H-W, Huang C-Y, Chu P-C, et al. 2010. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc. Natl. Acad. Sci. USA 107(34):15205-10
55. Tietze R, Jurgons R, Lyer S, Schreiber E, Wiekhorst F, et al. 2009. Quantification of drug-loaded magnetic nanoparticles in rabbit liver and tumor after in vivo administration. J. Magn. Magn. Mater. 321(10):1465-68
56. Alexiou C, Jurgons R, Schmid R, Hilpert A, Bergemann C, et al. 2005. In vitro and in vivo investigations of targeted chemotherapy with magnetic nanoparticles. J. Magn. Magn. Mater. 293(1):389-93
57. Schulze K, Koch A, Schopf B, Petri A, Steitz B, et al. 2005. Intraarticular applicationofsuperparamagnetic nanoparticles and their uptake by synovial membrane-an experimental study in sheep. J. Magn. Magn. Mater. 293(1):419-32
58. Forbes ZG, Yellen BB, Halverson DS, Fridman G, Barbee KA, Friedman G. 2008. Validation of high gradient magnetic field based drug delivery to magnetizable implants under flow. IEEE Trans. Biomed. Eng. 55(2):643-49
59. Chertok B, Moffat BA, David AE, Yu F, Bergemann C, et al. 2008. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 29(4):487-96
60. Dames P, Gleich B, Flemmer A, Hajek K, Seidl N, et al. 2007. Targeted delivery of magnetic aerosol droplets to the lung. Nat. Nano 2(8):495-99
61. Lee J-H, Huh Y-M, Jun Y, Seo J, Jang J, et al. 2006. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat. Med. 13(1):95-99
62. Yang L, Mao H, Wang YA, Cao Z, Peng X, et al. 2008. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 5(2):235-43
63. Chung HJ, Castro CM, Im H, Lee H, Weissleder R. 2013. A magneto-DNA nanoparticle system for rapid detection and phenotyping of bacteria. Nat. Nanotechnol. 8(5):369-75
64. Perez JM, Josephson L, O'Loughlin T, Högemann D, Weissleder R. 2002. Magnetic relaxation switches capable of sensing molecular interactions. Nat. Biotechnol. 20(8):816-20
65. Takeda S, Mishima F, Fujimoto S, Izumi Y, Nishijima S. 2007. Development of magnetically targeted drug delivery system using superconducting magnet. J. Magn. Magn. Mater. 311(1):367-71
66. Rotariu O, Strachan NJC. 2005. Modelling magnetic carrier particle targeting in the tumor microvas-culature for cancer treatment. J. Magn. Magn. Mater. 293(1):639-46
67. Feynman RP. 1970. Feynman Lectures on Physics. Boston: Addison Wesley Longman
68. Georgakilas V, Tzitzios V, Gournis D, Petridis D. 2005. Attachment ofmagnetic nanoparticles oncarbon nanotubes and their soluble derivatives. Chem. Mater. 17(7):1613-17
69. Kim D-H, Rozhkova EA, Ulasov IV, Bader SD, Rajh T, et al. 2010. Biofunctionalized magnetic-vortex microdiscs for targeted cancer-cell destruction. Nat. Mater. 9(2):165-71
70. Colombo M, Carregal-Romero S, Casula MF, Gutiérrez L, Morales MP, et al. 2012. Biological applications of magnetic nanoparticles. Chem. Soc. Rev. 41(11):4306-34
71. Puntes VF, Krishnan KM, Alivisatos AP. 2001. Colloidal nanocrystal shape and size control: the case of cobalt. Science 291(5511):2115-17
72. Cozzoli PD, Snoeck E, Garcia MA, Giannini C, Guagliardi A, et al. 2006. Colloidal synthesis and characterization of tetrapod-shaped magnetic nanocrystals. Nano Lett. 6(9):1966-72
73. Guardia P, Pérez N, Labarta A, Batlle X. 2010. Controlled synthesis of iron oxide nanoparticles over a wide size range. Langmuir 26(8):5843-47
74. 4/ZnS hollow nanospheres. J. Am. Chem. Soc. 131(32):11276-77
75. 4 (M = Fe, Co, Mn) nanoparticles. J. Am. Chem. Soc. 126(1):273-79
76. Gao J, Gu H, Xu B. 2009. Multifunctional magnetic nanoparticles: design, synthesis, and biomedical applications. Acc. Chem. Res. 42(8):1097-107
77. Lattuada M, Hatton TA. 2007. Preparation and controlled self-assembly of Janus magnetic nanoparticles. J. Am. Chem. Soc. 129(42):12878-89
78. 1 magnetic resonance imaging contrast agents for molecular imaging. Langmuir 23(8):4583-88
79. Cheon J, Kang N-J, Lee S-M, Lee J-H, Yoon J-H, Oh SJ. 2004. Shape evolution of single-crystalline iron oxide nanocrystals. J. Am. Chem. Soc. 126(7):1950-51
80. Park S, Kim S, Lee S, Khim ZG, Char K, Hyeon T. 2000. Synthesis and magnetic studies of uniform iron nanorods and nanospheres. J. Am. Chem. Soc. 122(35):8581-82
81. Kim D, Lee N, Park M, Kim BH, An K, Hyeon T. 2009. Synthesis of uniform ferrimagnetic magnetite nanocubes. J. Am. Chem. Soc. 131(2):454-55
82. An K, Kwon SG, Park M, Na HB, Baik S-I, et al. 2008. Synthesis of uniform hollow oxide nanoparticles through nanoscale acid etching. Nano Lett. 8( 12): 4252-58
83. Cabot A, Puntes VF, Shevchenko E, Yin Y, Balcells L, et al. 2007. Vacancy coalescence during oxidation of iron nanoparticles. J. Am. Chem. Soc. 129(34):10358-60
84. Han Q, Liu Z, Xu Y, Zhang H. 2007. Synthesis and magnetic properties of single-crystalline magnetite nanowires. J. Cryst. Growth 307(2):483-89
85. Lübbe AS, Alexiou C, Bergemann C. 2001. Clinical applications of magnetic drug targeting. J. Surg. Res. 95(2):200-6
86. Pankhurst QA, Connolly J, Jones SK, Dobson J. 2003. Applications of magnetic nanoparticles in biomedicine. J. Phys. D: Appl. Phys. 36(13):R167-81
87. Pankhurst QA, Thanh NTK, Jones SK, Dobson J. 2009. Progress in applications of magnetic nanopar-ticles in biomedicine. J. Phys. D: Appl. Phys. 42(22):224001
88. Nacev A, Komaee A, Sarwar A, Probst R, Kim SH, et al. 2012. Towards control of magnetic fluids in patients: directing therapeutic nanoparticles to disease locations. IEEE Control Syst. 32(3):32-74
89. Polyak B, Friedman G. 2009. Magnetic targeting for site-specific drug delivery: applications and clinical potential. Expert Opin. Drug Deliv. 6(1):53-70
90. Bawa R. 2008. Nanoparticle-based therapeutics in humans: a survey. Nanotech. Law Bus. 5:135-55
91. Schuknecht HF, Merchant SN, Nadol JB Jr. 2010. Schuknecht's Pathology of the Ear. Shelton, CT: PMPH. 3rd ed.
92. Stachler RJ, Chandrasekhar SS, Archer SM, Rosenfeld RM, Schwartz SR, et al. 2012. Clinical practice guideline: sudden hearing loss. Otolaryngol. Head Neck Surg. 146(Suppl. 3):S1-35
93. Natl. Inst. Deaf. Other Commun. Disord. (NIDCD) Epidemiol. Stat. Program. 2012. Prevalence of chronic tinnitus. Chart, NIDCD, updated May. http://www.nidcd.nih.gov/health/statistics/Pages/prevalence.aspx
94. Natl. Inst. Deaf. Other Commun. Disord. 2010. M énière's disease. NIH Publ. No. 10-3404, NIDCD, Bethesda, MD, updated July. http://www.nidcd.nih.gov/health/balance/pages/meniere.aspx
95. Salt AN, Plontke SK. 2005. Local inner-ear drug delivery and pharmacokinetics. Drug Discov. Today 10(19):1299-306
96. Radeloff A, Unkelbach MH, Tillein J, Braun S, Helbig S, et al. 2007. Impact of intrascalar blood on hearing. Laryngoscope 117(1):58-62
97. Juhn SK, Hunter BA, Odland RM. 2000. Blood-labyrinth barrier and fluid dynamics of the inner ear. Int. Tinnitus J. 7(2):72-83
98. Swan EEL, Mescher MJ, Sewell WF, Tao SL, Borenstein JT. 2008. Inner ear drug delivery for auditory applications. Adv. Drug Deliv. Rev. 60(15):1583-99
99. Li P, Zeng XL, Ye J, Yang QT, Zhang GH, Li Y. 2011. Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiol. Neurotol. 16(3):198-202
100. Plaza G, Herráiz C. 2007. Intratympanic steroids for treatment of sudden hearing loss after failure of intravenous therapy. Otolaryngol. Head Neck Surg. 137(1):74-78
101. Haynes DS, O'Malley M, Cohen S, Watford K, Labadie RF. 2007. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope 117(1):3-15
102. Rauch SD, Halpin CF, Antonelli PJ, Babu S, Carey JP, et al. 2011. Oral versus intratympanic cortico-steroid therapy for idiopathic sudden sensorineural hearing loss:arandomized trial.JAMA 305(20):2071-79
103. Chandrasekhar SS, Rubinstein RY, Kwartler JA, Gatz M, Connelly PE, et al. 2000. Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngol. Head Neck Surg. 122(4):521-28
104. Sorrells SF, Sapolsky RM. 2007. An inflammatory review of glucocorticoid actions in the CNS. Brain Behav. Immun. 21(3):259-72
105. Sholter DE, Armstrong PW. 2000. Adverse effects of corticosteroids on the cardiovascular system. Can. J. Cardiol. 16(4):505-11
106. Pisu M, James N, Sampsel S, Saag KG. 2005. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology (Oxford ) 44(6):781-88
107. Juhn SK. 1988. Barrier systems in the inner ear. Acta Otolaryngol. 105(S458):79-83
108. Labadie RF, Majdani O, Fitzpatrick JM. 2007. Image-guided technique in neurotology. Otolaryngol. Clin. North Am. 40(3):611-24
109. Kratchman LB, Schurzig D, McRackan TR, Balachandran R, Noble JH, et al. 2012. A manually operated, advance off-stylet insertion tool for minimally invasive cochlear implantation surgery. IEEE Trans. Biomed. Eng. 59(10):2792-800
110. Wang H, Northrop C, Liberman MC, Merchant SN. 2006.3-D virtual model ofahumantemporal bone.3D Virtual Model, Eaton-Peabody Lab., Mass. Eye Ear Infirm., Boston http://www.masseyeandear.org/research/ent/eaton-peabody/epl- imaging-resources/3-d-model-of-human-temporal-bone/
111. Wang H, Northrop C, Burgess B, Liberman MC, Merchant SN. 2006. Three-dimensional virtual model of the human temporal bone: a stand-alone, downloadable teaching tool. Otol. Neurotol. 27(4):452-57
112. Hu A, Parnes LS. 2009. Intratympanic steroids for inner ear disorders: a review. Audiol. Neurotol. 14(6):373-82
113. Rivera T, Sanz L, Camarero G, Varela-Nieto I. 2012. Drug delivery to the inner ear: strategies and their therapeutic implications for sensorineural hearing loss. Curr. Drug Deliv. 9(3):231-42
114. Salt AN, Plontke SK. 2009. Principles of local drug delivery to the inner ear. Audiol. Neurotol. 14(6):350-60
115. Slattery WH, Fisher LM, Iqbal Z, Friedman RA, Liu N. 2005. Intratympanic steroid injection for treatment of idiopathic sudden hearing loss. Otolaryngol. Head Neck Surg. 133(2):251-59
116. McCall AA, Swan EEL, Borenstein JT, Sewell WF, Kujawa SG, McKenna MJ. 2010. Drug delivery for treatment of inner ear disease: current state of knowledge. Ear Hear. 31(2):156-65
117. Piu F, Wang X, Fernandez R, Dellamary L, Harrop A, et al. 2011. OTO-104: a sustained-release dexamethasone hydrogel for the treatment of otic disorders. Otol. Neurotol. 32(1):171-79
118. Salt AN, Hartsock J, Plontke S, LeBel C, Piu F. 2011. Distribution of dexamethasone and preservation of inner ear function following intratympanic delivery of a gel-based formulation. Audiol. Neurotol. 16(5):323-35
119. Rarey KE, Lohuis PJ, Ten Cate WJ. 1991. Response of the stria vascularis to corticosteroids. Laryngoscope 101(10):1081-84
120. Silverstein H. 1999. Use of a new device, the MicroWick, to deliver medication to the inner ear. Ear Nose Throat J. 78(8):595-98, 600
121. Suryanarayanan R, Srinivasan VR, O'Sullivan G. 2009. Transtympanic gentamicin treatment using Silverstein MicroWick in Ménière's disease patients: long term outcome. J. Laryngol. Otol. 123(1):45-49
122. Weisskopf P, Hoffer ME, Kopke RD, Gottshall K, Allen K, Wester D. 2001. Microdose gentamicin delivered via the round window microcatheter: a therapeutic option in Menière's disease. Oper. Tech. Otolaryngol. Head Neck Surg. 12(3):154-56
123. Plontke SK, Zimmermann R, Zenner H-P, Löwenheim H. 2006. Technical note on microcatheter implantation for local inner ear drug delivery: surgical technique and safety aspects. Otol. Neurotol. 27(7):912-17
124. Lee KY, Nakagawa T, Okano T, Hori R, Ono K, et al. 2007. Novel therapy for hearing loss: delivery of insulin-like growth factor 1 to the cochlea using gelatin hydrogel. Otol. Neurotol. 28(7):976-81
125. Paulson DP, Abuzeid W, Jiang H, Oe T, O'Malley BW, Li D. 2008. A novel controlled local drug delivery system for inner ear disease. Laryngoscope 118(4):706-11
126. Endo T, Nakagawa T, Kita T, Iguchi F, Kim T-S, et al. 2005. Novel strategy for treatment of inner ears using a biodegradable gel. Laryngoscope 115(11):2016-20
127. Kopke RD, Wassel RA, Mondalek F, Grady B, Chen K, et al. 2006. Magnetic nanoparticles: inner ear targeted molecule delivery and middle ear implant. Audiol. Neurotol. 11(2):123-33
128. Shellock FG. 2001. Magnetic Resonance Procedures: Health Effects and Safety. Boca Raton, FL: CRC. 478 pp.
129. Schenck JF. 1996. The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds. Med. Phys. 23(6):815-50
130. Vignaud A, Mâitre X, Guillot G, Durand E, de Rochefort L, et al. 2005. Magnetic susceptibility matching at the air-tissue interface in rat lung by using a superparamagnetic intravascular contrast agent: influence on transverse relaxation time of hyperpolarized helium-3. Magn. Reson. Med. 54(1):28-33
131. Skumryev V, Blythe HJ, Cullen J, Coey JMD. 1999. AC susceptibility of a magnetite crystal. J. Magn. Magn. Mater. 196:515-17
132. Heider F, Zitzelsberger A, Fabian K. 1996. Magnetic susceptibility and remanent coercive force in grown magnetite crystals from 0.1 μm to 6 mm. Phys. Earth Planet. Inter. 93(3-4):239-56
133. Dunlop DJ. 1984. A method of determining demagnetizing factor from multidomain hysteresis. J. Geophys. Res.: Solid Earth 89(B1):553-58
134. Grief AD, Richardson G. 2005. Mathematical modelling of magnetically targeted drug delivery. J. Magn. Magn. Mater. 293(1):455-63
135. Mikkelsen CI. 2005. Magnetic separation and hydrodynamic interactions in microfluidic systems. PhD Thesis, Dep. Micro Nanotechnol., Tech. Univ. Denmark, Kongens Lyngby
136. Sarwar A, Nemirovski A, Shapiro B. 2012. Optimal Halbach permanent magnet designs for maximally pulling and pushing nanoparticles. J. Magn. Magn. Mater. 324(5):742-54
137. Shapiro B, Dormer K, Rutel IB. 2010. A two-magnet system to push therapeutic nanoparticles. AIP Conf. Proc. 1311(1):77-88
138. Sarwar A, Lee R, Depireux DA, Shapiro B. 2013. Magnetic injection of nanoparticles into rat inner ears at a human head working distance. IEEE Trans. Magn. 49(1):440-52
139. Depireux D, Lee R, Sarwar A, Shapiro B. 2012. Drug delivery to the inner ear of rats using magnetically steered nanoparticles. Presented at Mid-Winter Meet. Assoc. Res. Otolaryngol., Feb. 25-29, San Diego, CA
140. Cherry DK, Woodwell DA. 2002. National ambulatory medical care survey: 2000 summary. Adv. Data (328):1-32
141. Rosenfeld RM, Casselbrant ML, Hannley MT. 2001. Implications of the AHRQ evidence report on acute otitis media. Otolaryngol. Head Neck Surg. 125(5):439-48
142. Cent. Dis. Control. Prev. (CDC). 2014. NAMCS and NHAMCS web tables. Ambul. Health Care Data, CDC, Atlanta, updated Feb. 24. http://www.cdc.gov/nchs/ ahcd/web-tables.htm#2010
143. Rovers MM. 2008. The burden of otitis media. Vaccine 26(Suppl. 7):G2-4
144. Kenna MA. 2005. Otitis media and the new guidelines. J. Otolaryngol. 34(Suppl. 1):S24-32
145. Grubb MS, Spaugh DC. 2010. Treatment failure, recurrence, and antibiotic prescription rates for different acute otitis media treatment methods. Clin. Pediatr. 49(10):970-75
146. Ryan AF, Jung TTK, Juhn SK, Li J-D, Andalibi A, et al. 2005. Recent advances in otitis media. 4A. Molecular biology. Ann. Otol. Rhinol. Laryngol. Suppl. 194:42-49
147. Lim DJ, Birck H. 1971. Ultrastructural pathology of the middle ear mucosa in serous otitis media. Ann. Otol. Rhinol. Laryngol. 80(6):838-53
148. Tos M, Bak-Pedersen K. 1976. Goblet cell population in the pathological middle ear and eustachian tube of children and adults. Ann. Otol. Rhinol. Laryngol. 86(2 Pt. 1):209-18
149. Klein JO. 2000. The burden of otitis media. Vaccine 19(Suppl. 1):S2-8
150. Teele DW, Klein JO, Rosner BA. 1984. Otitis media with effusion during the first three years of life and development of speech and language. Pediatrics 74(2):282-87
151. Subcomm. Manag. Acute Otitis Media. 2004. Diagnosis and management of acute otitis media. Pediatrics 113(5):1451-65
152. Shehab N, Patel PR, Srinivasan A, Budnitz DS. 2008. Emergency department visits for antibiotic-associated adverse events. Clin. Infect. Dis. 47(6):735-43
153. Hoberman A, Paradise JL, Rockette HE, Shaikh N, Wald ER, et al. 2011. Treatment of acute otitis media in children under 2 years of age. N. Engl. J. Med. 364(2):105-15
154. Tähtinen PA, Laine MK, Huovinen P, Jalava J, Ruuskanen O, Ruohola A. 2011. A placebo-controlled trial of antimicrobial treatment for acute otitis media. N. Engl. J. Med. 364(2):116-26
155. Kogan MD, Overpeck MD, Hoffman HJ, Casselbrant ML. 2000. Factors associated with tympanostomy tube insertion among preschool-aged children in the United States. Am. J. Public Health 90(2):245-50
156. Hoskison E, Daniel M, Al-Zahid S, Shakesheff K, Bayston R, Birchall J. 2013. Drug delivery to the ear. Ther. Deliv. 4(1):115-24
157. Khoo X, Simons EJ, Chiang HH, Hickey JM, Sabharwal V, et al. 2013. Formulations for trans-tympanic antibiotic delivery. Biomaterials 34(4):1281-88
158. Campbell WR, Johnson RH, Paulsen NE. 2008. Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear. US Patent No. 20080269187 A1
159. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, et al. 2004. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122(4):564-72
160. Lee PP, Feldman ZW, Ostermann J, Brown DS, Sloan FA. 2003. Longitudinal prevalence of major eye diseases. Arch. Ophthalmol. 121(9):1303-10
161. Eye Dis. Preval. Res. Group. 2004. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 122(4):477-85
162. Natl. Eye Inst. (NEI). 2013. Facts about age-related macular degeneration. Fact Sheet, NEI, Bethesda, MD, reviewed July. http://www.nei.nih. gov/health/maculardegen/armd-facts.asp#10
163. Green WR, Enger C. 2005. Age-related macular degeneration histopathologic studies: the 1992 Lorenz E. Zimmerman Lecture. Retina 25(5 Suppl.):1519-35
164. Michels S, Schmidt-Erfurth U, Rosenfeld PJ. 2006. Promising new treatments for neovascular age-related macular degeneration. Expert Opin. Investig. Drugs 15(7):779-93
165. Peyman GA, Herbst R. 1974. Bacterial endophthalmitis: treatment with intraocular injection of gen-tamicin and dexamethasone. Arch. Ophthalmol. 91(5):416-18
166. Husain D, Kramer M, Kenny AG, Michaud N, Flotte TJ, et al. 1999. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Investig. Ophthalmol. Vis. Sci. 40(10):2322-31
167. Dorin G. 2004. Evolution of retinal laser therapy: minimum intensity photocoagulation (MIP). Can the laser heal the retina without harming it? Semin. Ophthalmol. 19(1-2):62-68
168. McMeel JW, Trempe CL, Franks EB. 1977. Diabetic maculopathy. Trans. Sect. Ophthalmol. Am. Acad. Ophthalmol. Otolaryngol. 83(3 Pt. 1):OP476-87
169. Gillies MC, Sutter FKP, Simpson JM, Larsson J, Ali H, Zhu M. 2006. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113(9):1533-38
170. Berson EL. 1993. Retinitis pigmentosa: the Friedenwald Lecture. Investig. Ophthalmol. Vis. Sci. 34(5):1659-76
171. Hartong DT, Berson EL, Dryja TP. 2006. Retinitis pigmentosa. Lancet 368(9549):1795-809
172. Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, et al. 1993. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch. Ophthalmol. 111(6):761-72
173. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJS, et al. 2006. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trialof CNTF deliveredby encapsulated cell intraocular implants. Proc. Natl. Acad. Sci. USA 103(10):3896-901
174. Shantha TR, Shantha J. 2011. Retinitis pigmentosa treatment. US Patent No. 20120101033 A1
175. Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, et al. 2008. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. USA 105(39):15112-17
176. Narfström K, Katz ML, Ford M, Redmond TM, Rakoczy E, Bragadóttir R. 2003. In vivo gene therapy in young and adult RPE65-/-dogs produces long-term visual improvement. J. Hered. 94(1):31-37
177. Mello CC, Kramer JM, Stinchcomb D, Ambros V. 1991. Efficient gene transfer in C. elegans: extrachromosomal maintenance and integration of transforming sequences. EMBO J. 10(12):3959-70
178. Green M, Thorburn A, Kern R, Loewenstein PM. 2007. The use of cell microinjection for the in vivo analysis of viral transcriptional regulatory protein domains. Methods Mol. Med. 131:157-86
179. Williamson TH. 1997. Central retinal vein occlusion: What's the story? Br. J. Ophthalmol. 81(8):698-704
180. Soubrane G. 1999. Macular edema in retinal vein occlusion: up-date from the central retinal vein occlusion study. Doc. Ophthalmol. 97(3-4):279-82
181. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, et al. 2010. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117(6):1134-46.e3
182. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, et al. 2011. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology 118(12):2453-60
183. Jonas JB, Kreissig I, Degenring RF. 2002. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefe's Arch. Clin. Exp. Ophthalmol. 240(9):782-83
184. Laatikainen L, Kohner EM, Khoury D, Blach RK. 1977. Panretinal photocoagulation in central retinal vein occlusion: a randomised controlled clinical study. Br. J. Ophthalmol. 61(12):741-53
185. Hayreh SS, Klugman MR, Podhajsky P, Servais GE, Perkins ES. 1990. Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. Graefe's Arch. Clin. Exp. Ophthalmol. 228(4):281-96
186. Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, et al. 2003. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am. J. Ophthalmol. 136(5):791-96
187. Ciulla TA, Starr MB, Masket S. 2002. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology 109(1):13-24
188. Taban M, Behrens A, Newcomb RL, Nobe MY, Saedi G, et al. 2005. Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch. Ophthalmol. 123(5):613-20
189. West ES, Behrens A, McDonnell PJ, Tielsch JM, Schein OD. 2005. The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population increased between 1994 and 2001. Ophthalmology 112(8):1388-94
190. Olson JC, Flynn HW Jr, Forster RK, Culbertson WW. 1983. Results in the treatment of postoperative endophthalmitis. Ophthalmology 90(6):692-99
191. Winward KE, Pflugfelder SC, Flynn HW Jr, Roussel TJ, Davis JL. 1993. Postoperative Propionibacterium endophthalmitis: treatment strategies and long-term results. Ophthalmology 100(4):447-51
192. Gaudana R, Ananthula HK, Parenky A, Mitra AK. 2010. Ocular drug delivery. AAPS J. 12(3):348-60
193. Barar J, Javadzadeh AR, Omidi Y. 2008. Ocular novel drug delivery: impacts of membranes and barriers. Expert Opin. Drug Deliv. 5(5):567-81
194. Xu Q, Kambhampati SP, Kannan RM. 2013. Nanotechnology approaches for ocular drug delivery. Middle East Afr. J. Ophthalmol. 20(1):26-37
195. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, et al. 2010. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Investig. Ophthalmol. Vis. Sci. 51(11):5403-20
196. Al-Saikhan FI. 2013. The gene therapy revolution in ophthalmology. Saudi J. Ophthalmol. 27(2):107-11
197. Jager RD, Aiello LP, Patel SC, Cunningham ET. 2004. Risks of intravitreous injection: a comprehensive review. Retina 24(5):676-98
198. Kalam MA, Sultana Y, Samad A, Ali A, Aqil M, et al. 2008. Gelrite-based in vitro gelation ophthalmic drug delivery system of gatifloxacin. J. Dispers. Sci. Technol. 29(1):89-96
199. Alonso MJ, Sánchez A. 2003. The potential of chitosan in ocular drug delivery. J. Pharm. Pharmacol. 55(11):1451-63
200. Callanan D, Williams P. 2008. Topical nepafenac in the treatment of diabetic macular edema. Clin. Ophthalmol. 2(4):689-92
201. Weiner AL, Gilger BC. 2010. Advancements in ocular drug delivery. Vet. Ophthalmol. 13(6):395-406
202. Prow T, Grebe R, Merges C, Smith JN, McLeod DS, et al. 2006. Nanoparticle tethered antioxidant response element as a biosensor for oxygen induced toxicity in retinal endothelial cells. Mol. Vis. 12:616-25
203. Prow TW, Bhutto I, Kim SY, Grebe R, Merges C, et al. 2008. Ocular nanoparticle toxicity and trans-fection of the retina and retinal pigment epithelium. Nanomed.: Nanotechnol. Biol. Med. 4(4):340-49
204. Dengler M, Saatchi K, Dailey JP, Matsubara J, Mikelberg FS, et al. 2010. Targeted delivery of magnetic cobalt nanoparticles to the eye following systemic administration. AIP Conf. Proc. 1311(1):329-36
205. Raju HB, Hu Y, Vedula A, Dubovy SR, Goldberg JL. 2011. Evaluation of magnetic micro-and nanopar-ticle toxicity to ocular tissues. PLoS ONE 6(5):e17452
206. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. 1999. Oxidative damage and age-related macular degeneration. Mol. Vis. 5:32
207. Beatty S, Koh H-H, Phil M, Henson D, Boulton M. 2000. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 45(2):115-34
208. Humayun MS, Prince M, de Juan E Jr, Barron Y, Moskowitz M, et al. 1999. Morphometric analysis of the extramacular retina from postmortem eyes with retinitis pigmentosa. Investig. Ophthalmol. Vis. Sci. 40(1):143-48
209. Shen Z, Nacev A, Sarwar A, Lee R, Depireux D, Shapiro B. 2013. Automated fluorescence and reflectance coregistered 3-D tissue imaging system. IEEE Trans. Magn. 49(1):279-84
210. Shen Z, Nacev A, Shapiro B. 2012. Fluorescence and reflectance co-registered 3D tissue imaging system based on a cryostat. Presented at Int. Conf. Sci. Clin. Appl. Magn. Carriers, 9th, Minneapolis, MN
211. Kummer MP, Abbott JJ, Kratochvil BE, Borer R, Sengul A, Nelson BJ. 2010. OctoMag: an electromagnetic system for 5-DOF wireless micromanipulation. IEEE Trans. Robot. 26(6):1006-17
212. Ergeneman O, Chatzipirpiridis G, Pokki J, Marin-Suárez M, Sotiriou GA, et al. 2012. In vitro oxygen sensing using intraocular microrobots. IEEE Trans. Biomed. Eng. 59(11):3104-9
213. Ullrich F, Bergeles C, Pokki J, Ergeneman O, Erni S, et al. 2013. Mobility experiments with microrobots for minimally invasive intraocular surgery. Investig. Ophthalmol. Vis. Sci. 54(4):2853-63
214. Bergeles C, Kummer MP, Kratochvil BE, Framme C, Nelson BJ. 2011. Steerable intravitreal inserts for drug delivery:in vitro and ex vivo mobility experiments. InMedical Image Computing and Computer-Assisted Intervention-MICCAI 2011, ed. G Fichtinger, A Martel, T Peters, pp. 33-40. Berlin: Springer
215. Gupta PK, Jensen PS Jr, de Juan E Jr. 1999. Surgical forces and tactile perception during retinal microsurgery. In Medical Image Computing and Computer-Assisted Intervention-MICCAI 1999, ed. C Taylor, A Colchester, pp. 1218-25. Berlin: Springer
216. Singhy SPN, Riviere CN. 2002. Physiological tremor amplitude during retinal microsurgery. Proc. IEEE 28th Annu. Northeast Bioeng. Conf., Philadelphia, pp. 171-72. New York: IEEE
217. Jagtap AD, Riviere CN. 2004. Applied force during vitreoretinal microsurgery with handheld instruments. Proc. 26th Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. (IEMBS '04), 1:2771-73. New York: IEEE
218. Mathieu JB, Martel S. 2009. IMP-aggregation of magnetic microparticles in the context of targeted therapies actuated by a magnetic resonance imaging system. J. Appl. Phys. 106(4):044904
219. Evans BA, Shields AR, Carroll RL, Washburn S, Falvo MR, Superfine R. 2007. Magnetically actuated nanorod arrays as biomimetic cilia. Nano Lett. 7(5):1428-34
220. Cordente N, Respaud M, Senocq F, Casanove M-J, Amiens C, Chaudret B. 2001. Synthesis and magnetic properties of nickel nanorods. Nano Lett. 1(10):565-68
221. Nacev A, Beni C, Bruno O, Shapiro B. 2011. The behaviors of ferro-magnetic nano-particles in and around blood vessels under applied magnetic fields. J. Magn. Magn. Mater. 323(6):651-68
222. Nacev A, Beni C, Bruno O, Shapiro B. 2010. Magnetic nanoparticle transport within flowing blood and into surrounding tissue. Nanomedicine 5(9):1459-66
223. Nacev A, Kim SH, Rodriguez-Canales J, Tangrea MA, Shapiro B, Emmert-Buck MR. 2011. A dynamic magnetic shift method to increase nanoparticle concentration in cancer metastases: a feasibility study using simulations on autopsy specimens. Int. J. Nanomed. 6(1):2907-23
224. Renkin EM. 1954. Filtration, diffusion, and molecular sieving through porous cellulose membranes. J. Gen. Physiol. 38(2):225-43
225. Ogston AG, Preston BN, Wells JD. 1973. On the transport of compact particles through solutions of chain-polymers. Proc. R. Soc. Lond. A Math. Phys. Sci. 333(1594):297-316
226. Kulkarni S, Nacev A, Ramaswamy B, Depireux D, Shapiro B. 2013. Understanding motion of magnetic nanoparticles in tissue. Presented at Front. Biomagn. Nanopart. III, June 2-5, Telluride, CO
227. Salt AN, Ohyama K, Thalmann R. 1991. Radial communication between the perilymphatic scalae of the cochlea. II: Estimation by bolus injection of tracer into the sealed cochlea. Hear. Res. 56(1-2):37-43
228. Hiemenz PC, Rajagopalan R. 1997. Principles of Colloid and Surface Chemistry. Boca Raton, FL: CRC. 676 pp. 3rd ed.
229. Saltzman WM. 2001. Drug Delivery: Engineering Principles for Drug Therapy. New York: Oxford Univ. Press
230. Fournier RL. 2007. Basic Transport Phenomena in Biomedical Engineering. New York: Taylor & Francis
231. Lai SK, O'Hanlon DE, Harrold S, Man ST, Wang Y-Y, et al. 2007. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. USA 104(5):1482-87
232. Lai SK, Wang Y-Y, Hanes J. 2009. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61(2):158-71
233. Sun C, Lee J, Zhang M. 2008. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev. 60(11):1252-65
234. Weizenecker J, Gleich B, Rahmer J, Dahnke H, Borgert J. 2009. Three-dimensional real-time in vivo magnetic particle imaging. Phys. Med. Biol. 54(5):L1-10
235. 1 magnetic resonance imaging contrast agents. J. Am. Chem. Soc. 133(32):12624-31
236. Weinberg IN, Stepanov PY, Fricke ST, Probst R, Urdaneta M, et al. 2012. Increasing the oscillation frequency of strong magnetic fields above 101 kHz significantly raises peripheral nerve excitation thresholds. Med. Phys. 39(5):2578-83
237. Gleich B, Weizenecker J. 2005. Tomographic imaging using the nonlinear response of magnetic particles. Nature 435(7046):1214-17
238. Rahmer J, Antonelli A, Sfara C, Tiemann B, Gleich B, et al. 2013. Nanoparticle encapsulationinred blood cells enables blood-pool magnetic particle imaging hours after injection. Phys. Med. Biol. 58(12):3965-77